Therapeutic and Predicted Significance of PKLR in Patients With Cholangiocarcinoma.
Low PKLR expression in cholangiocarcinoma is associated with poor survival, indicating its potential as a prognostic biomarker.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpusSummary and findings
This study investigated the role of PKLR in cholangiocarcinoma (CCA) using transcriptomics and whole-exome sequencing. The analysis included 255 CCA samples from a published dataset and 36 samples from The Cancer Genome Atlas. Findings suggest that low PKLR expression correlates with poor survival outcomes in CCA patients.
Abstract
<h4>Background</h4>Cholangiocarcinoma (CCA) is a highly heterogeneous malignancy with a poor prognosis. However, the molecular mechanisms underlying CCA and its treatment options remain unclear and limited.<h4>Aims</h4>This study aims to identify novel prognostic biomarkers and potential therapeutic targets for CCA through transcriptomics and whole-exome sequencing analysis.<h4>Methods and results</h4>We analyzed the relationship between overall survival and various risk factors in 255 CCA samples from a published dataset and 36 samples from The Cancer Genome Atlas (TCGA) database. Transcriptomics analysis was used to identify genes whose expression plays a crucial role in CCA development and progression. Targeted drug databases were used to examine which gene expression signatures represent potential therapeutic targets for CCA. Mutated genes were analyzed to explore potential mechanisms. Standard statistical methods were applied to analyze associations between clinical data and candidate targets. A nomogram was constructed to predict the prognostic impact of the optimal candidate. Cell experiments were used to demonstrate the role of PKLR in CCA growth and metastasis. We identified FOLH1, PKLR, PTH1R, GPR114, KCNH2, LCN2, MMP10, PORCN, RIPK3, and SRPK3 as potential therapeutic targets for CCA, with PKLR being the most promising candidate based on the computational analyses. PKLR was lowly expressed in CCA tissues. PKLR expression was closely associated with ARID1A and KRAS mutations. PKLR mRNA levels were significantly correlated with tumor size (p = 0.024) and metastasis (p = 0.014). Low PKLR expression in CCA was positively associated with poor survival. A nomogram accurately predicted the prognosis of CCA patients based on PKLR expression levels. Silencing PKLR expression promotes growth and metastasis of CCA in vitro.<h4>Conclusion</h4>Our findings indicate that PKLR, an independent protective factor in CCA, is a potential prognostic biomarker and a candidate for further investigation as a therapeutic target. PKLR expression is significantly associated with ARID1A and KRAS mutations.
Background
Cholangiocarcinoma (CCA) is a malignancy known for its heterogeneity and poor prognosis. Previous studies have identified various risk factors and molecular mechanisms, but there remains a need for reliable prognostic biomarkers and therapeutic targets. This study aims to fill that gap by focusing on the gene PKLR and its association with CCA outcomes.
Methods
The study analyzed 255 CCA samples from a published dataset and 36 samples from The Cancer Genome Atlas (TCGA). Transcriptomics analysis was performed to identify gene expression patterns, and standard statistical methods were applied to assess associations between clinical data and candidate targets. A nomogram was constructed to predict prognostic impact based on PKLR expression.
Results
Low PKLR expression was significantly correlated with tumor size (p = 0.024) and metastasis (p = 0.014). The study also found that low PKLR expression was positively associated with poor survival outcomes in CCA patients. Additionally, silencing PKLR expression promoted growth and metastasis of CCA in vitro.
Interpretation
The findings suggest that PKLR may serve as a prognostic biomarker in CCA, aligning with previous literature that highlights the importance of gene expression in cancer progression. However, the clinical significance of PKLR as a therapeutic target remains uncertain, particularly given the reliance on retrospective data and in vitro experiments. The study's limitations, including potential confounding factors and the nature of the data, should be considered when interpreting the results.
Key findings
- PKLR mRNA levels were significantly correlated with tumor size (p = 0.024).
- PKLR mRNA levels were significantly correlated with metastasis (p = 0.014).
- Low PKLR expression in CCA was positively associated with poor survival.
Limitations
- Retrospective data analysis.
- Small sample size from TCGA.
- In vitro findings may not translate to clinical outcomes.
- No direct causal relationship established.